<DOC>
	<DOCNO>NCT00002545</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Randomized phase III trial study effectiveness radiation therapy carmustine treat patient supratentorial glioblastoma multiforme .</brief_summary>
	<brief_title>Radiation Therapy Plus Chemotherapy Treating Patients With Supratentorial Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : I . Determine whether use radiosurgery ( stereotactic external-beam irradiation ) prior conventional radiotherapy carmustine ( BCNU ) improve overall survival compare conventional radiotherapy plus BCNU alone patient supratentorial glioblastoma multiforme . II . Determine compare frequency severity toxicity associate regimen . III . Compare effect two regimen neurologic function quality life . OUTLINE : Randomized study . Arm I : Radiotherapy plus Single-Agent Chemotherapy . Tumor irradiation use megavoltage equipment ( least 4 MV photon ) ; plus Carmustine , BCNU , NSC-409962 . Arm II : Radiosurgery follow Radiotherapy plus Single-Agent Chemotherapy . Stereotactic tumor irradiation ; follow tumor irradiation Arm I ; plus BCNU . PROJECTED ACCRUAL : 200 patient enter approximately 3 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histopathologically confirm supratentorial glioblastoma multiforme gliosarcoma Diagnosis surgical biopsy resection require The following tumor type specifically exclude : Astrocytoma atypical anaplastic feature Well differentiate astrocytomas Tumors originate brain stem Tumors locate within 10 mm optic chiasm Infratentorial tumor Multifocal malignant glioma Recurrent malignant glioma Well circumscribe contrastenhancing tumor pre postoperative contrastenhanced CT MRI maximum diameter ( direction ) 40 mm require Tumors enhance postoperative CT MRI exclude Concurrent enrollment RTOG9308 encourage PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 3 month Hematopoietic : ANC least 1,500 Platelets least 100,000 Hb least 10 g/dl ( may transfuse ) Hepatic : Bilirubin great 2.0 mg/dl SGOT SGPT great 2 x normal Renal : Creatinine great 1.5 mg/dl BUN great 25 mg/dl Pulmonary : Chest xray normal If abnormal history pulmonary disease , pulmonary function study ( include DLCO ) must least 75 % predict Other : Neurologic function status 03 No AIDS No major medical psychiatric illness would preclude protocol therapy followup No second malignancy within 5 year except : Nonmelanomatous skin cancer In situ carcinoma uterine cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy head neck Surgery : No 5 week surgery initiation treatment Recovery surgery postoperative complication require</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>